Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
about
Altered radiation fractionation schedules for clinically localised and locally advanced prostate cancerA comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancerRationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancerMeta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and BenefitsIntraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancersThe effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis.Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysisHypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.Exploring two two-edged swords.Hypofractionated external-beam radiotherapy for prostate cancer.Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialThe emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boostRandomized trial of hypofractionated external-beam radiotherapy for prostate cancer.Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.Quality of Life and Sexual Health in the Aging of PCa Survivors.Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.Molecular targets for radiation oncology in prostate cancer.What do we know about the α/β for prostate cancer?Defining a dose-response relationship for prostate external beam radiotherapy.Individualized image-based lymph node irradiation for prostate cancer.What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.From radiobiology to technology: what is changing in radiotherapy for prostate cancer.A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators.Emerging applications of stereotactic body radiotherapy.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.Progress and controversies: Radiation therapy for prostate cancer.Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience.Hypofractionated radiotherapy for prostate cancer.
P2860
Q24186971-ACF6967A-A314-4E25-9B63-C13D3CDDBCD3Q26738278-4178A3B3-4610-4FCA-9ABB-36BB139B385CQ26774847-13D57FEF-4878-4717-A521-AEF8104F53A1Q26824608-4E2204C2-1C24-4043-BDC1-8951F702681DQ26830442-93A827A2-7E59-40B6-B7AF-CCBC3D6F3ABEQ26998991-8CCF4D06-FC5C-40F6-966C-EA9872EF2F3EQ28559812-DC745DC4-E179-4903-8693-D1E0987BDBD2Q35166901-47D7F111-1958-406D-BD7F-9DC3C4BD8B17Q35201788-647E08A7-4939-4C52-B16F-A86EA7946C3BQ35530488-9F982516-EB50-4786-9442-669D87719BD9Q35649108-50D44142-D353-4993-AD9B-03FC3AA21129Q35686316-D177D623-BDC5-4226-BF85-29AC9D3637DEQ36214859-A18CF61A-5ECA-4C92-9B52-BC786B2EA3E3Q36604355-848C5620-3B9B-46F1-9A3B-D8BF88D8DAC2Q36611916-F1613D43-C22A-4F29-BF16-D8855F86B653Q36711751-FCE19624-0904-4A9A-867B-8A08D18E2BEEQ36798868-CF777C25-374B-478F-834B-4CCD515DDA55Q37128114-EB635D78-ED3A-4BC4-87B7-695CC66EEB8EQ37154093-34B892ED-F2B9-40B2-8242-2D039E7F0F1CQ37175207-26C940E0-66C3-464D-AA49-1D224405E445Q37176535-F0B0B074-7289-4934-BF8E-74F66EF1BE44Q37249348-F1C7CE00-6135-41DF-986A-8A6279E2097FQ37436220-107CF955-C797-46EC-B808-57F52A0DCDD8Q37512971-227A6D01-26AA-4B00-A21B-2899D4AFF6C9Q37586877-860B7FA8-8285-41E2-A211-C62AA4E36F80Q37686901-6CF68223-D43C-4FD8-8786-C4A53CFFDFC2Q37725623-966C23F0-3814-4454-9CAF-2E057884B81AQ37730056-4713699C-B3F4-4A85-820B-AADD4CB0B13CQ38014447-7FE1D775-91E3-48D3-88DE-1003B965421EQ38023478-BB0D4399-3D35-4EC7-9F60-9CA5C902E3A2Q38095668-07E1F854-3A9A-4586-8DE1-FF8D7E206060Q38109812-852D07C7-A45B-4BAF-9312-A9DCE63335AFQ38172228-D9149475-7D93-4A0E-B9D4-B1C8444BD022Q38191990-EC348DE5-D452-442C-9AF8-332328EAF08DQ38198096-D2A966D7-1355-41AC-AD4D-A0792C4984B4Q38221693-80BBA4D0-9749-4481-8BCE-91319F9A1871Q38226822-15F6897C-5AB8-4394-A626-29CE848EB1F5Q38252429-92DD2151-2F05-4913-9985-9DC1124D1043Q38276603-F0175457-C687-48B3-9004-E91BAB24794EQ38283897-4D3B561C-A981-45D3-9C79-CC8A3F644DAA
P2860
Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@en
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@nl
type
label
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@en
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@nl
prefLabel
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@en
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@nl
P2093
P1476
Dose-fractionation sensitivity ...... asets: α/β = 1.4 (0.9-2.2) Gy.
@en
P2093
Eduardo Zubizarreta
Jolyon H Hendry
Raymond Miralbell
P304
P356
10.1016/J.IJROBP.2010.10.075
P407
P577
2011-02-15T00:00:00Z